clenoliximab


Also found in: Wikipedia.

clenoliximab

Immunology An anti-CD4 immunotherapeutic for treating rheumatoid arthritis, possibly also severe asthma and psoriasis. See Monoclonal antibody.
References in periodicals archive ?
On August 7, 2000 IDEC announced that it has begun a multi-center, Phase II clinical trial with the company's PRIMATIZED(R), non-depleting, anti-CD4 monoclonal antibody, Clenoliximab (IDEC-151).
Once bound to CD4, Clenoliximab is believed to regulate helper T-cell function, but without depleting T cells and affecting other important immune system functions.
IDEC Pharmaceuticals (Nasdaq:IDPH) today announced that it has begun a multi-center, Phase II clinical trial with the company's PRIMATIZED(R), non-depleting, anti-CD4 monoclonal antibody, Clenoliximab (IDEC-151).